Edith Perez, MD, Oncology, Jacksonville, FL

EdithAdaljisaPerezMD

Oncology Jacksonville, FL

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Vice President and Head, U.S. BioOncology Medical Unit at Genentech, Inc.; Director, Breast Cancer Translational Genomics Program at Mayo Clinic; Member, Board of Directors of the American Association for Cancer Research

Dr. Perez is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Perez's full profile

Already have an account?

Education & Training

  • VA Medical CenterFellowship, Hematology, 1984 - 1987
  • Loma Linda UniversityResidency, Internal Medicine, 1979 - 1982
  • University of Puerto Rico School of MedicineClass of 1979
  • University of Puerto RicoB.S., Biology, Magna Cum Laude, 1975

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1995 - 2022
  • MN State Medical License
    MN State Medical License 1995 - 1996
  • CA State Medical License
    CA State Medical License 1980 - Present
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Expert - Breast Cancer Expertscape, 2014
  • Claude Jacquillat Award International Congress on Anticancer Treatment, 2014
  • Giants of Cancer Care Award OncLive, 2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer  
    Northfelt DW, Allred JB, Liu HS, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, Am J Clin Oncol, 4/1/2014
  • International study on inter-reader variability for circulating tumor cells in breast cancer  
    Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothe F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavro..., Breast Cancer Res, 1/1/2014
  • Adjuvant exemestane with ovarian suppression in premenopausal breast cancer  
    Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA , Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr,..., N Engl J Med, 1/1/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Targeting hsp90 in breast cancer: ENCHANT-1 (nct01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2-positive o...
    Cameron D, Spector N, Gomez H, Hickish T, Vandat L, Kim SB, Sheldon E, El-Hariry I, Perez EA, Awada A, Eur J Cancer, 3/1/2014
  • Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic bre...
    Perez EA, Lopez-Vega JM, Petit T, Zamagni C, Freudensprung U, Bastiere-Truchot L, Walker R, Andersson M, Eur J Cancer, 3/1/2014
  • Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
    Adams S, Gray R, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA, Badve SS, Cancer Res, 12/1/2013
  • Join now to see all

Lectures

  • Updates on Metastatic Breast Cancer: HER2+ 
    Amelia Island, FL - 1/1/2014
  • Breast Cancer: New Advances in Breast Cancer Management 
    Wichita, KS - 1/1/2014
  • State of the Art Anti-HER2 Therapies for Breast Cancer 
    Dublin, Ireland - 1/1/2014
  • Join now to see all

Other

  • ALTTO Trials Findings For Treating HER2+ Breast Cancer - Mayo Clinic. 
    Perez EA, Mayo Clinic
    6/1/2014
  • Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial. 
    Perez EA, OncLive
    6/1/2014
  • The Race Against Breast Cancer: What Mayo Clinic Has Learned So Far. 
    Perez EA, Thompson EA, Mayo Clinic
    2/1/2014
  • Join now to see all

Press Mentions

  • Chutes & Ladders—Immunomedics Taps Ipsen Exec Semerjian as CEO
    Chutes & Ladders—Immunomedics Taps Ipsen Exec Semerjian as CEOApril 10th, 2020
  • Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer
    Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical OfficerApril 9th, 2020
  • Stand up to Cancer Commits to Making Clinical Trials More Diverse
    Stand up to Cancer Commits to Making Clinical Trials More DiverseFebruary 4th, 2020
  • Join now to see all

Grant Support

  • Role Of Immunity In Efficacy Of Chemotherapy PLUS TrastuzumabNational Cancer Institute2011–2012
  • Predictive Biomarkers Of Adjuvant Trastuzumab In The Her2+N9831 Intergroup TrialNational Cancer Institute2008–2011
  • Breast CancerNational Cancer Institute2001–2002

Professional Memberships